206 results on '"Borchmann, Sven"'
Search Results
2. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA
3. FDG-Positronenemissionstomographie-Computertomographie und neue Chancen zur Therapiesteuerung
4. Clinical applications of circulating tumor DNA in Hodgkin lymphoma
5. Procarbazine-induced Genomic Toxicity in Hodgkin Lymphoma Survivors
6. Plasma Circulating Tumor DNA Sequencing Reveals the Landscape of Acquired Mutations in Patients with Hepatocellular Carcinoma: a Potential Predictive Value in Liquid Biopsy
7. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
8. Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR
9. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection
10. Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1
11. Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphoma.
12. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA
13. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
14. An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
15. S236: HIGH-BREADTH SEQUENCING OF CIRCULATING TUMOR DNA IDENTIFIES NOVEL CLASSIFICATION OF HODGKIN LYMPHOMA
16. P1384: MULTI-EFFECTOR IMMUNE CELL RETARGETING USING A BISPECIFIC SINGLE-CHAIN VARIABLE FRAGMENT LIBRARY IN AGGRESSIVE B CELL LYMPHOMAS
17. P1209: PERIPHERAL BLOOD CTDNA-SEQUENCING ENABLES PREDICTION OF OUTCOMES IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA USING A DYNAMIC RISK MODEL
18. Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)
19. Supplementary Tables from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
20. Supplementary Figures from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
21. Data from Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
22. Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma
23. Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
24. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)
25. P046: Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
26. P037: High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
27. P059: Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
28. Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors
29. EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
30. Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment
31. Hodgkin lymphoma in elderly patients
32. Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma
33. The genetics of Hodgkin lymphoma: an overview and clinical implications
34. Coming of age: the evolving role of circulating tumor DNA in malignant lymphoma
35. Abstract LBA010: Therapeutic stimulation of nucleic acid receptor RIG-I enhances efficacy of kinase inhibitor treatment in oncogene-driven tumors
36. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
37. Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma
38. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
39. Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle
40. Additional file 2 of An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
41. Additional file 4 of An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
42. Wer ist ... Sven Borchmann?
43. Exhaustive circulating tumor DNA sequencing reveals the genomic landscape of Hodgkin lymphoma and facilitates ultrasensitive detection of minimal residual disease
44. Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients
45. An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer
46. Liquid biopsy in lymphoma: Molecular methods and clinical applications
47. Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche
48. Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication
49. Reinduction therapy with everolimus in combination with dexamethasone, high‐dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD‐R3i)
50. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.